Table 1.

Published TDP-43 ubiquitinylation sites

Ubiquitinylation sites	TDP-43 species	Cell type	Treatment	Method	Refs.
Lys-102, Lys-114, Lys-145, Lys-181	Insoluble overexpressed TDP-43 and TDP-S6	HEK-293		LC-MS/MS	30
Lys-181	Overexpressed TDP-43-ΔNLS-Lys-145Q	QBI293		TDP-43 IP followed by nano-LC/nanospray/MS/MS	67
Lys-114	Endogenous	HEK-293		LC-MS/MS	35
Lys-102, Lys-160	Endogenous	MV4-11	MG-132
Lys-95, Lys-102, Lys-114, Lys-160, Lys-181	Endogenous	HCT116	Bortezomib	LC-MS/MS	34
Lys-102, Lys-114, Lys-121, Lys-140, Lys-145, Lys-160, Lys-176, Lys-181, Lys-263	Endogenous	Myeloma cell lines
Lys-79	Endogenous TDP-43 from Sarko-sylinsoluble human ALS brain			LC-MS/MS	13